Phase II study of NGR-hTNF plus doxorubicin in relapsed ovarian cancer (OC).
G. Scambia
No relevant relationships to disclose
D. Lorusso
No relevant relationships to disclose
G. Amadio
No relevant relationships to disclose
N. Trivellizzi
No relevant relationships to disclose
A. Pietragalla
No relevant relationships to disclose
R. De Vincenzo
No relevant relationships to disclose
V. Salutari
No relevant relationships to disclose
M. Di Stefano
No relevant relationships to disclose
G. Mangili
No relevant relationships to disclose
S. Montoli
No relevant relationships to disclose
G. Citterio
No relevant relationships to disclose
A. Lambiase
Employment or Leadership Position - MolMed S.p.A.
C. Bordignon
Employment or Leadership Position - MolMed S.p.A.